P.S Thought it most appropriate to tag this question with parted-magic, ramfs (or tmpfs... Not sure how to identify which one is in use) and low-disk-space like tags, but alas there doesn't appear to be any of them. If the community doesn't want to create one/all, please feel free to suggest other tags that others feel are appropriate.
Most of these are tmpfs style things (non of them are actual mounted partitions anyway) that exist in RAM. df can still accurately report usage. If you don't see a / entry under Parted magic, I guess they are using some kind of esoteric naming. Another hint that you are using the wrong tool for the job.
Parted Magic Torrent
Mod note: this is not official Netgear firmware and will not be supported by Netgear Download link for latest build here; _V1_Transmission_Firmware I have made a new firmware with built in Transmission-daemon torrent client , based on firmware V1.0.0.17_1.0.17 with some updates. 1) format your USB hdrive/stick with an ext3 filesystem (formatted as a hard disk with partition table), [suggest if not using Linux to do this from Parted Magic or any live boot distro.] 2) create a folder on it in the root 'transmissionbt' 3) flash firmware When the router boots, if it sees a drive and that folder it will start transmission-daemon and set some default options for it. (/tranmissionbt/settings.json will contain all the settings, this is available by browsing to the router via samba, you will need to read the info on transmissions site about these settings if you are not familiar with it) The web interface will then be available here (link on normal web interface); :55555 I will write further details including what is updated/sources/patches etc. later I just thought I would give anyone who wants a play with it a chance first. Dropbear ssh server is also running, using l:admin p: (whatever your web password is) if you want to poke about, telnet is disabled. Link (assuming Mega works) !AVpnFZjb!AhN33SXTgd-aIEhoAH7SxjG6dVUApRQd8RxOam9sMYI MD5 ea451ae6e34c48e66292cd1237791413 DGND3700_03021748_A_D.chk
By Argelio R. Dumenigo The sidelines at the friendly football games George Rathmann *51 played in during his graduate school days at Princeton were frequented by some hard-hitting intellectuals. On any given afternoon, Nobel laureate Albert Einstein or future winner John Nash *50 might stroll over to the field outside Frick Laboratory, where Rathmann and his chemistry classmates would play touch football as a break from research, classes, and experiments. No matter what Rathmann did on the makeshift gridiron, the 6'-4" former Milwaukee high school basketball star would have been hard to miss. Encounters with scientific luminaries such as Einstein and J. Robert Oppenheimer were just as hard to ignore — and left a lasting impression on the man who would essentially create the biotechnology industry. "There was a lot of magic," says Rathmann. That magic must have rubbed off on him. In 1980 he founded Amgen, Inc. — today the world's largest independent biotechnology company — which in turn gave rise to the $22.3-billion U.S. biotechnology industry. Equated with inventors such as Henry Ford and Benjamin Franklin, Rathmann is treated within his field "with a reverence otherwise reserved for favorite teams and Mom," as one biotech industry writer put it. "It's one thing to start a company and it's another to manage spectacular growth successfully, and he's demonstrated extraordinary talent," says Patrick McGeer *52, who once worked and played alongside Rathmann and is now professor emeritus of neurological research at the University of British Columbia. Rathmann jokes, "I'm almost always viewed by business people as one of the best scientists they know and I'm almost always viewed by scientists as one of the best business people they know. Now the common denominator is that I'm not much of a scientist or a business man." In truth, he's both. At Amgen, Rathmann's research and development experience, coupled with his charming smile and outgoing personality, helped turn the $18-million startup into a multi-billion operation. The company's focus on proteins and recombinant DNA technology — the transfer of a gene from one organism into another organism, literally DNA from different sources that have been recombined — led to the development of treatments such as Amgen's first product, Epogen. The red-blood cell stimulant, which supplements the supply of the naturally occurring substance produced by healthy kidneys called erythropoietin, is used by dialysis patients suffering from anemia. The company later used the same recombinant DNA technology to develop Neupogen, a white-blood cell stimulator that aids in fighting infections for people undergoing chemotherapy for cancer. Combined, the two products had sales of nearly $3 billion in 1999. More important, says Rathmann, they helped people go on with their daily lives. That human side of his work is something that touches Rathmann deeply. At Alumni Day in February, when he was awarded the James Madison Medal for distinguished graduate alumni, he delivered a speech in which he flipped to a slide of a woman on dialysis whose health improved dramatically after taking Epogen. The burly entrepreneur had to hold back tears as he told the audience about the patient's daughter, who thanked him for giving her mother back to her. The enriched lives that come with successful treatments is the reason Rathmann has spoken out through the years about the new-drug approval process at the U.S. Food and Drug Administration. Currently, it can take up to 12 years and nearly $500 million to get a medication through the process and into the hands of patients. "We ought to attempt to do better and be aware of the fact that the so-called safe path of rejection and delaying and preventing something from being tested seems safe because it means that nothing can go wrong," says Rathmann. "All you have to do is be exposed to a critically ill population, some members of which perish before a lifesaving drug is available, and you realize that, wow, if we could have saved six weeks or 10 weeks we could have saved that life. We could have changed that person's state of health by an enormous amount. I think that message has to be there all the time." Rathmann, who now chairs the board at Hyseq in Sunnyvale, California, and at Seattle's ZymoGenetics, which recently went public, has watched the biotechnology field grow from about eight U.S. companies in 1980 to an estimated 1,273 in 2000, according to the Biotechnology Industry Organization. Rathmann's personal fortune has grown along with the industry. He now travels in his own jet — a far cry from the $25 car Rathmann sold to his classmate McGeer when the pair parted ways at graduation. "That car would never have made it to Illinois," McGeer quips. That's where Rathmann and his wife, Joy, were headed after graduation, for a job at 3M. Rathmann worked at 3M for 21 years, where, among other accomplishments, he aided in the development of one of the company's signature products, Scotchgard. He moved on to Litton Industries in 1972 and later to Abbott Laboratories, where he served as vice president of research and development before leaving to start Amgen. Rathmann cofounded another biotech firm, ICOS, in 1990. The Washington-based company, which focuses on protein-based and small-molecule therapeutics, got off the ground with $30 million in initial funding, including $5 million from Microsoft magnate Bill Gates. Rathmann is credited with later wooing another round of funding from Gates by matching the billionaire's investment dollar-for-dollar. Despite his success, Rathmann is not afraid to admit that he's had his share of failure. "I've been associated with some pretty big disappointments at some companies and I've watched some others have disasters, but you can come out whole after a short time and actually learn from the experience," he says. "There are very few things that can happen that are irreversibly damaging to your career, to your attitude, and to your ability to contribute." His current contributions at Hyseq focus on research involving the sequencing of genes with an eye towards the development of treatments for cardiovascular diseases, cancer, and inflammatory and infectious diseases. Rathmann is excited by the advances made in the sequencing of the human genome during the last few years, not only for the boost they give his industry, but for the potential they have to wipe out common diseases and conditions. Although he, like many others, initially thought the breakthroughs in genetic research would be a shortcut for success, Rathmann realizes there is a lot of research and testing ahead. "The sequencing of the human genome last year was a positive jolt for the whole field of biotechnology. A lot of stocks benefited from more enthusiasm, more visibility, more general confidence that this was going to change how we do things — and it will — but it's going to be another few years before we see the real benefits. We've barely scratched the surface of what its impact is going to be," he explains. "It's kind of fun to watch it unfold." Rathmann's excitement over research is what led him to Princeton. He earned his undergraduate degree in physical chemistry at Northwestern University in 1948 in just three years, and it was his senior adviser at Northwestern, Robert Burwell, Jr. *36, who suggested Princeton to him. Once on campus, Rathmann says he was inspired by professors who gave their graduate students plenty of attention, including Charles Smyth '16 *17, Walter Kauzmann *40, and Hugh Stott Taylor, who headed the chemistry department from 1926 to 1951. Smyth, his thesis adviser, served as Rathmann's mentor before the term was trendy, Rathmann says. "He was an inspiration because he was always right. He was very careful about facts and very thorough. If he took a sharp pencil to any paper you wrote, it was always vastly improved," he recalls. Dean Taylor, who was later knighted by the Queen of England, was dedicated to keeping his students abreast of new developments, Rathmann says. "Dean Taylor almost invariably came to physical chemistry class with a recent issue of the Journal of Physical Chemistry under his arm and you just knew that he was anxious to keep us current and actively interested in the emerging science of the time," he remembers. Rathmann still follows Taylor's example, staying on top of scientific advances, even though the chairman and CEO titles he has held could have shifted him away from it. "I think that a person who is strictly a manager and has lost interest in the science, or never really wanted to bother with it, really has severe limitations in leading new efforts on scientific frontiers," he says. There are plenty of new efforts in biotechnology right now. With more than 350 biotech drug products and vaccines currently in clinical trials targeting more than 200 diseases, including various cancers, Alzheimer's disease, heart disease, diabetes, multiple sclerosis, AIDS, and arthritis, the future of the biotechnology industry looks bright, says Rathmann. But he says that a drop in investments is definitely taking a toll on many companies, which have been forced to lay people off or shut their doors altogether. "We've gone through a longer period of time than I could remember of really tough times for financing, and in our system we believe it should be on your shoulders to raise money and get your job done," he says. "But I think the industry is still thriving. If you look at the pace of discovery, it has not slackened at all, even though there has been a lot of pressure on companies to make ends meet. The opportunities today, I feel, are as great as they ever were." Argelio R. Dumenigo is PAW's associate editor. 2ff7e9595c
Comments